Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 11/20 | 0.38 |
| ▸ | METAP1 | P53582 | 6/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CAD | P27708 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9353137 | 0.87 | TSHR (0.36) | TYRSMN1; SMN2TSHRL3MBTL1 | |
| SCHEMBL536251 | 0.83 | TYR (0.39) | TYRSMN1; SMN2TSHR | |
| SCHEMBL9845864 | 0.82 | SMN1; SMN2 (0.39) | SMN1; SMN2L3MBTL1 | |
| SCHEMBL11189746 | 0.80 | METAP2 (0.46) | METAP2METAP1TYRLMNAHTT | |
| SCHEMBL22751568 | 0.80 | METAP2 (0.46) | METAP2METAP1TYRLMNAHTT | |
| SCHEMBL9845863 | 0.79 | SMN1; SMN2 (0.36) | SMN1; SMN2L3MBTL1 | |
| SCHEMBL9845893 | 0.79 | SMN1; SMN2 (0.36) | SMN1; SMN2L3MBTL1 | |
| SCHEMBL9480087 | 0.78 | CTSK (0.44) | GAA | |
| SCHEMBL9480524 | 0.75 | CTSK (0.42) | GAA | |
| SCHEMBL9480506 | 0.75 | CTSK (0.42) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240215572-A1 | ANTIMICROBIAL PARTICLE DISPERSION | MITSUBISHI PENCIL COMPANY, LIMITED (JP) | 2024-07-04 | — | — | US | claimed |
| US-20170215421-A1 | BIOCIDE AGENTS | LANXESS DEUTSCHLAND GMBH (DE) | 2017-08-03 | — | — | US | claimed |
| EP-2779830-B1 | STABILIZATION OF COMPOUNDS CONTAINING IODINE HAVING POLYMERS COMPRISING NITROGEN | LANXESS DEUTSCHLAND GMBH (DE) | 2017-05-17 | — | — | EP | claimed |
| US-9585384-B2 | Stabilization of compounds comprising iodine | LANXESS DEUTSCHLAND GMBH (DE) | 2017-03-07 | — | — | US | claimed |
| EP-3125688-A1 | BIOCIDE AGENTS | LANXESS Deutschland GmbH (DE) | 2017-02-08 | — | — | EP | claimed |
| US-20160360753-A1 | BIOCIDIC MICROCAPSULES | LANXESS DEUTSCHLAND GMBH (DE) | 2016-12-15 | — | — | US | claimed |
| US-9326502-B2 | Stabilization of compounds containing iodine having polymers comprising nitrogen | LANXESS DEUTSCHLAND GMBH (DE) | 2016-05-03 | — | — | US | claimed |
| WO-2015150430-A1 | BIOCIDE AGENTS | LANXESS DEUTSCHLAND GMBH (DE) | 2015-10-08 | — | — | WO | claimed |
| EP-2926659-A1 | Biocidal agent | LANXESS Deutschland GmbH (DE) | 2015-10-07 | — | — | EP | claimed |
| US-20140303277-A1 | STABILIZATION OF COMPOUNDS CONTAINING IODINE HAVING POLYMERS COMPRISING NITROGEN | LANXESS DEUTSCHLAND GMBH (DE) | 2014-10-09 | — | — | US | claimed |
| WO-2013072427-A1 | STABILIZATION OF COMPOUNDS CONTAINING IODINE HAVING POLYMERS COMPRISING NITROGEN | LANXESS DEUTSCHLAND GMBH (DE) | 2013-05-23 | — | — | WO | claimed |
| EP-2594132-A1 | Stabilisation of iodine containing compounds with polymers containing nitrogen | Lanxess Deutschland GmbH (DE) | 2013-05-22 | — | — | EP | claimed |
| WO-2012076699-A1 | BIOCIDE MICROCAPSULE FORMULATIONS CONTAINING STABILISED IODINE-CONTAINING COMPOUNDS | LANXESS DEUTSCHLAND GMBH (DE) | 2012-06-14 | — | — | WO | claimed |
| EP-2462805-A1 | Formulations containing stabilised compounds containing iodine | LANXESS Deutschland GmbH (DE) | 2012-06-13 | — | — | EP | claimed |
| EP-2440044-A2 | INORGANIC CARRIER MATERIALS CONTAINING NITROGEN | Lanxess Deutschland GmbH (DE) | 2012-04-18 | — | — | EP | claimed |
| US-20110009268-A1 | IPBC-CONTAINING COACERVATES | LANXESS DEUTSCHLAND GMBH (DE) | 2011-01-13 | — | — | US | claimed |
| EP-2270087-A1 | Heterocyclic 3-ring connections and polymers containing iodine compounds | LANXESS Deutschland GmbH (DE) | 2011-01-05 | — | — | EP | claimed |
| WO-2010142795-A2 | INORGANIC CARRIER MATERIALS CONTAINING NITROGEN | LANXESS DEUTSCHLAND GMBH (DE) | 2010-12-16 | — | — | WO | claimed |
| EP-1981629-A1 | IPBC-CONTAINING COACERVATES | Lanxess Deutschland GmbH (DE) | 2008-10-22 | — | — | EP | claimed |
| WO-2007087994-A1 | IPBC-CONTAINING COACERVATES | LANXESS DEUTSCHLAND GMBH (DE) | 2007-08-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303277-A1 | STABILIZATION OF COMPOUNDS CONTAINING IODINE HAVING POLYMERS COMPRISING NITROGEN | NISCH, INMT, TPO | METAP2 975/4885METAP1 1147/4885TYR 67/4885 |
| US-20240215572-A1 | ANTIMICROBIAL PARTICLE DISPERSION | Q6ZSR9, PAM, ACMSD | METAP2 4341/4885METAP1 3789/4885TYR 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.